Literature DB >> 9476911

Idiopathic pneumonia syndrome in mice after allogeneic bone marrow transplantation.

G Shankar1, J S Bryson, C D Jennings, P E Morris, D A Cohen.   

Abstract

Pulmonary complications are a major clinical problem following allogeneic bone marrow transplantation (BMT), contributing to more than 30% of transplant-related mortalities. Idiopathic pneumonia syndrome is responsible for significant mortality among BMT patients. However, the etiology of injury to the lung parenchyma by this disease syndrome is unknown and it has been difficult to evaluate the cellular and molecular mechanisms underlying IPS in the absence of a suitable animal model. To study post-BMT lung disease during graft-versus-host disease (GVHD), we have developed a murine model that utilizes a semi-allogeneic parental --> F1 transplant strategy to induce a mild form of GVHD. Progressive inflammatory lung disease developed in animals with mild GVHD, as indicated by changes in immune cell distribution and cytokine expression in the lungs of transplanted animals. Histologic analysis of lung tissue from GVHD mice at 3 wk post-BMT showed minor immunopathologic changes compared with control mice. In contrast, lungs of GVHD mice at 12 wk displayed histopathologic hallmarks of interstitial pneumonitis, such as prominent perilumenal mononuclear cell infiltration and areas of alveolar congestion. Flow cytometric analysis of lung interstitial cells of GVHD mice revealed an increase in CD8+ T-cells at week 3, which decreased to normal levels by week 12 post-BMT. Simultaneously, the percentage of CD4+ T-cells increased progressively above normal levels and peaked at week 7 post-BMT. Analysis of cytokine mRNA expression in lung tissue indicated that steady state levels of interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha, interferon-gamma, and IL-12 were significantly elevated in lungs of GVHD mice at 3 wk post-BMT compared with untreated controls. Mice that were transplanted with allogeneic bone marrow alone (BMT controls) also displayed elevated expression of these cytokines, although only IL-6 was significantly higher than in untreated controls. In contrast, at 12 wk after transplantation only TNF-alpha and IL-12 levels remained elevated in GVHD mice, suggesting prolonged macrophage activation. On the basis of these findings, we conclude that allogeneic bone marrow transplantation in this mouse model causes a progressive interstitial pneumonitis, which is characterized by an acute influx of CD8+ T-cells, followed in the chronic phase by a prominent accumulation of CD4+ T-cells, and is associated with persistent production of cytokines known to activate macrophages.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9476911     DOI: 10.1165/ajrcmb.18.2.2988

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  12 in total

Review 1.  An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome.

Authors:  Angela Panoskaltsis-Mortari; Matthias Griese; David K Madtes; John A Belperio; Imad Y Haddad; Rodney J Folz; Kenneth R Cooke
Journal:  Am J Respir Crit Care Med       Date:  2011-05-01       Impact factor: 21.405

2.  Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice.

Authors:  Yu Yu; Dapeng Wang; Chen Liu; Kane Kaosaard; Kenrick Semple; Claudio Anasetti; Xue-Zhong Yu
Journal:  Blood       Date:  2011-08-19       Impact factor: 22.113

3.  High-resolution computed tomography features of pulmonary chronic graft-versus-host disease following hematopoietic stem cell transplantation: histopathological correlation.

Authors:  Noriyo Yanagawa; Fumikazu Sakai; Noriko Kamata; Tsunekazu Hishima; Tamiko Takemura; Kazuteru Ohashi
Journal:  Jpn J Radiol       Date:  2011-02-27       Impact factor: 2.374

Review 4.  Translational research efforts in biomarkers and biology of early transplant-related complications.

Authors:  Sophie Paczesny; Maribel Diaz-Ricart; Enric Carreras; Enrique Carerras; Kenneth R Cooke
Journal:  Biol Blood Marrow Transplant       Date:  2011-01       Impact factor: 5.742

Review 5.  Idiopathic pneumonia syndrome after bone marrow transplantation: the role of pre-transplant radiation conditioning and local cytokine dysregulation in promoting lung inflammation and fibrosis.

Authors:  G Shankar; D A Cohen
Journal:  Int J Exp Pathol       Date:  2001-04       Impact factor: 1.925

6.  Dynamics of early histopathological changes in GVHD after busulphan/cyclophosphamide conditioning regimen.

Authors:  Sulaiman Al-Hashmi; Zuzana Hassan; Behnam Sadeghi; Björn Rozell; Moustapha Hassan
Journal:  Int J Clin Exp Pathol       Date:  2011-07-31

Review 7.  Murine models of chronic graft-versus-host disease: insights and unresolved issues.

Authors:  Yu-Waye Chu; Ronald E Gress
Journal:  Biol Blood Marrow Transplant       Date:  2008-02-13       Impact factor: 5.742

8.  c-Rel is an essential transcription factor for the development of acute graft-versus-host disease in mice.

Authors:  Yu Yu; Dapeng Wang; Kane Kaosaard; Chen Liu; Jianing Fu; Kelley Haarberg; Claudio Anasetti; Amer A Beg; Xue-Zhong Yu
Journal:  Eur J Immunol       Date:  2013-07-04       Impact factor: 5.532

9.  Increase of interleukin-18 serum levels after engraftment correlates with acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation.

Authors:  Sebastian Scholl; Herbert G Sayer; Lars-Olof Mügge; Christoph Kasper; Marko Pietraszczyk; Kay-Oliver Kliche; Joachim H Clement; Klaus Höffken
Journal:  J Cancer Res Clin Oncol       Date:  2004-09-07       Impact factor: 4.553

10.  Immunosuppressive mechanisms of human bone marrow derived mesenchymal stromal cells in BALB/c host graft versus host disease murine models.

Authors:  Joseph Delano Robles; Yin Ping Liu; Jiamin Cao; Zheng Xiang; Yin Cai; Michael Manio; Eva Hc Tang; Godfrey Chi-Fung Chan
Journal:  Exp Hematol Oncol       Date:  2015-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.